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Abstract
The uptake of predictive DNA testing in families with a hereditary disease is <50%. 
Current practice often relies on the proband to inform relatives about the possibility 
of predictive DNA testing, but not all relatives are informed adequately. To enable 
informed decision-making concerning predictive DNA testing, the approach used to 
inform at-risk relatives needs to be optimized. This study investigated the prefer-
ences of patients, relatives, and the general population from the Netherlands on how 
to inform relatives at risk of autosomal dominant diseases. Online surveys were sent 
to people with autosomal dominant neuro-, onco-, or cardiogenetic diseases and their 
relatives via patient organizations (n = 379), and to members of the general population 
via a commercial panel (n = 1,000). Attitudes of the patient and population samples 
generally corresponded. A majority believed that initially only first-degree relatives 
should be informed, following the principles of a cascade screening approach. Most 
participants also thought that probands and healthcare professionals (HCPs) should 
be involved in informing relatives, and a large proportion believed that HCPs should 
contact relatives directly in cases where patients are unwilling to inform, both for 
untreatable and treatable conditions. Participants from the patient sample were of 
the opinion that HCPs should actively offer support. Our findings show that both pa-
tients and HCPs should be involved in informing at-risk relatives of autosomal domi-
nant diseases and suggest that relatives' ‘right to know’ was considered a dominant 
issue by the majority of participants. Further research is needed on how to increase 
proactive support in informing of at-risk relatives.
K E Y W O R D S
attitudes, autosomal dominant disease, beliefs, cascade screening, cascade testing, 
communication, ethics, family, genetics services, inherited predisposition, population 
perspectives, service delivery models, survey design
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1  | INTRODUC TION
In hereditary diseases with an autosomal dominant inheritance pat-
tern, which includes the majority of hereditary cardiac, oncological, 
and neurological diseases, first-degree relatives are at 50% risk of 
carrying the genetic predisposition (Miller, Wang, & Ware, 2013). 
Predictive DNA testing is possible for at-risk relatives when a patho-
genic variant is identified in the proband (the first affected person in 
the family in whom a DNA test is performed). It is important to allow 
genotype-positive relatives to participate in preventive management 
strategies when available (Miller et al., 2013). Predictive DNA testing 
also allows at-risk relatives to make informed decisions regarding life 
choices and to consider their reproductive options in case of a child 
wish. Genotype-negative relatives can be reassured about disease 
risk in themselves and their offspring (Miller et al., 2013).
In current Dutch practice, the genetic counselor asks the proband 
in whom a pathogenic variant is identified to inform relatives about 
the possibility of predictive DNA testing. This is referred to as the 
'family-mediated' approach (Christiaans, Birnie, Bonsel, Wilde, & van 
Langen, 2008; Leenen et al., 2016). This family-mediated approach 
is also described in previous research conducted in other, Western 
countries (Godard, Hurlimann, Letendre, & Egalite, 2006; Schwiter, 
Rahm, Williams, & Sturm, 2018). Depending on the country and clinic, 
the genetic counselor can provide a family letter to help probands 
inform at-risk relatives (Burns, Ingles, & James, 2018; Christiaans et 
al., 2008; Leenen et al., 2016; Menko et al., 2013; Young et al., 2019; 
Dheensa, Lucassen, & Fenwick, 2018). Previous research indicates 
that relatives generally appreciate being informed by someone from 
their family, as this is the most personal and logical approach (Whyte, 
Green, McAllister, & Shipman, 2016; Wiseman, Dancyger, & Michie, 
2010). However, previous studies have only been performed in pro-
bands and relatives attending genetic counseling. Uptake studies in 
onco- and cardiogenetic diseases found that about half the relatives 
attend genetic counseling, specifically 53% in women and 12% in 
men in BRCA1/2 in the UK (Brooks et al., 2004), 39% in hypertro-
phic and dilated cardiomyopathy (Miller et al., 2013) and 60% in long 
QT syndrome in Australia (Burns, McGaughran, Davis, Semsarian, & 
Ingles, 2016), and 39% in hypertrophic cardiomyopathy (Christiaans 
et al., 2008) and 57% in different inherited cardiac diseases in the 
Netherlands (Van der Roest, Pennings, Bakker, van den Berg, & van 
Tintelen, 2009). A systematic review of Menko et al. (2018) on up-
take in hereditary cancers showed that uptake rates ranged from 
21% to 44% for hereditary breast and ovarian cancer, and 41 to 94% 
in Lynch syndrome, based on reports of genetic centers in different 
countries. This suggests that some relatives are not adequately in-
formed or not informed at all. This was recently illustrated by a legal 
case in the United Kingdom, in which relatives were not informed 
about the hereditary disease in their family. This case questioned the 
duty of healthcare professionals (HCPs) to inform at-risk relatives 
(Lucassen & Gilbar, 2018).
Considering the low uptake of genetic counseling and predictive 
DNA testing, researchers from different countries proposed a more 
active role for HCPs in the information process in which HCPs have 
direct contact with relatives (Aktan-Collan et al., 2007; Menko et 
al., 2018; Sermijn et al., 2016; Suthers, Armstrong, McCormack, & 
Trott, 2006). However, more active approaches to inform relatives 
have seldomly been used in patient care. In Denmark, a direct con-
tact approach is used for contacting at-risk relatives by the national 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC) register, 
showing support by 78% of relatives and 82% of the general pop-
ulation (Petersen et al., 2019). In the past, a direct contact has been 
used in the Netherlands in familial hypercholesterolemia as part of 
a temporary national screening program (Van Maarle, Stouthard, 
Marang-Van de Mheen, Klazinga, & Bonsel, 2001). However, using 
more active approaches raises questions regarding psychological, 
legal, and ethical issues: Would direct contact cause psychological 
harm in relatives and harm to family relationships? Do HCPs have a 
duty to warn at-risk relatives? How can we respect the right not to 
know? How do the right not to know and the right on privacy conflict 
with the duty to warn, and how should we handle this?
To our knowledge, there have only been a few quantitative stud-
ies that have assessed the attitudes of patients and relatives regard-
ing how they prefer at-risk relatives to be informed and how these 
ethical issues should be handled on group level, and these studies 
were often part of larger studies on attitudes toward genetic testing 
(Gilbar et al., 2016; Leenen et al., 2016). None of these studies in-
cluded members of the general population. Attitudes of the general 
population are specifically of interest as they are a proxy for rela-
tives unaware of a hereditary disease in their family and can help us 
explore the opinions of relatives who do not attend genetic counsel-
ing. Incorporating the attitudes and preferences could improve the 
approach used to inform at-risk relatives.
This survey study aimed (a) to assess the preferences for how 
at-risk relatives should be informed, and by whom, and (b) to inves-
tigate attitudes regarding ethical issues related to informing at-risk 
relatives. By asking both the patient population and the general pop-
ulation from the Netherlands to participate, we could compare their 
attitudes regarding their approach used to inform at-risk relatives. 
This study was conducted to inform a Dutch clinical guideline on 
informing at-risk relatives of hereditary diseases.
2  | METHODS
2.1 | Participants
Two groups of participants were asked to fill out a survey: (a) a Dutch 
patient sample of adult patients with an autosomal dominant neuro-
logical, oncological, or cardiac disease and adult first- and further-
degree relatives of patients with such a disease, including relatives 
who carry the genetic variant and relatives who do not; and (b) a 
Dutch general population sample of adults in the general population 
without a known hereditary disease themselves or in their family.
Participants with a hereditary disease themselves or in their 
family were asked to fill out the survey via Dutch patient or-
ganizations (see Supplementary Material S1). Members of the 
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general population were asked to participate using a Dutch online 
commercial survey panel focused on health research questions 
(FlyCatcher, 2019). The panel members, participants who agreed 
to take part in FlyCatcher surveys, approached for this study were 
selected to reflect the Dutch population based on demographic 
characteristics that included age, income level, education level, 
and place of residence. Participation in FlyCatcher surveys is 
voluntary.
2.2 | Procedures
This survey study was conducted between February and April 2018 
in the Netherlands. The surveys were administered via an online 
survey system; SurveyMonkey was used for the patient sample sur-
vey, and FlyCatcher's self-developed survey system was used for 
the general population sample (FlyCatcher, 2019; Survey Monkey 
Inc. 2019). Participants recruited via relevant patient organizations 
were invited by e-mail or by a link on the website or social media 
of relevant patient organizations. Participants recruited through 
the online commercial panel gave consent to participate in several 
surveys about health issues. These participants received a mon-
etary incentive for completing the survey. Participants received an 
e-mail with a link to the survey. Prior to entering the online survey, 
information about the aims of the study, the study design, and con-
tact details of the investigators were provided. Entering the online 
survey was considered as providing informed consent. Participants 
could exit the survey at any time. Participation was anonymous, 
and no personal data were collected.
To ensure that participants fulfilled the inclusion criteria, they 
were first asked whether they had a hereditary disease themselves 
or in their family. For the patient survey, participants who indicated 
they had an autosomal recessive or X-linked disease themselves or 
in their family, or did not have any hereditary disease in their family, 
were excluded. For the general population survey, participants who 
indicated they had a hereditary disease themselves or in their family 
were excluded.
2.3 | Instrumentation
Different survey arms were designed for the patient versus the 
population sample. The survey for the patient sample was de-
signed by a psychologist (LvdH), a clinical geneticist (IC), and a 
policy-worker of the VSOP, Dutch Patient Alliance for Rare and 
Genetic diseases (DS). LvdH and IC constructed the survey for the 
population sample. The themes addressed in the surveys were 
identical and were identified by conducting focus groups with 
HCPs and interviews with probands and relatives (Van den Heuvel 
et al., 2019). HCPs, including clinical geneticists, genetic coun-
selors, and psychosocial workers, and representatives of patient 
organizations were asked to provide input and comments on the 
survey.
The surveys contained multiple-choice items complemented 
by open answer items. Sociodemographic factors were assessed 
using the same items in both surveys, including gender, age, ed-
ucation level (categorized in low, moderate, or high education 
level), marital status, religion, and parenthood. For the patient 
sample, participants were also asked about the disease diagnosed 
in themselves/their family. The surveys addressed the follow-
ing questions: (a) ‘Do people wish to be informed about genetic 
risks?’; (b) ‘Which relatives should be informed?’; (c) ‘Who should 
inform at-risk relatives?’; (d) ‘How should information for relatives 
be provided?’; and (e) ‘How should ethical issues be handled, such 
as whether direct contact by HCPs with at-risk relatives without 
consent of the proband would be justified, and whether contact 
details of at-risk relatives can be requested from the population 
register?’ Patients and relatives were additionally asked about 
their opinions regarding the experienced support and follow-up 
contact by the clinical genetic centers.
The population sample was asked the same questions, but vi-
gnettes were included to inform them about hereditary diseases, 
inheritance pattern, and possible preventive or treatment and re-
productive options, with the first vignette describing a case of he-
reditary breast and ovarian cancer (i.e., in the vignette considered a 
treatable condition) and the second describing a case of hereditary 
Alzheimer's disease (i.e., considered an untreatable condition). For 
the patient sample, participants themselves indicated which dis-
ease was diagnosed in themselves/their family, and these diseases 
were categorized by clinical geneticists as ‘treatable’ (prevention 
or treatment of the disease is possible) or ‘untreatable’ (prevention 
or treatment of the disease is not possible). English translations of 
the surveys are shown in Supplementary Material S2.
2.4 | Data analysis
Frequency and descriptive statistics were used to describe the 
sociodemographic and clinical characteristics of the study sam-
ple and the responses on each survey item. Differences between 
sociodemographic and clinical factors were assessed using chi-
square tests (all categorical variables). Chi-square or Fisher's exact 
tests were also used to assess differences in sociodemographic 
and clinical factors with regard to responses on survey items. A 
Freeman–Halton extension of the Fisher exact test was used in 
case more than 20% of cells had expected count <5. A Bonferroni-
corrected two-sided p-value of <.05 was considered significant. 
Effect sizes were reported in the form of Cramer's V 's (described 
in the results as V ), with Cramer's V < 0.20 considered as a weak 
relationship, 0.20–0.30 as a moderate relationship, and >0.30 as a 
strong relationship. SPSS version 24 was used to perform statisti-
cal analyses (IBM Corporation, 2016). LvdH conducted thematic 
coding analysis on open answers (Braun & Clarke, 2006). Based 
on coding analysis, a codebook was developed with which themes 
and subthemes were derived. Analysis of open answers was used 
to supplement the data.
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3  | RESULTS
3.1 | Response rate and demographics
In total, 1,379 participants completed the survey: 1,000 partici-
pants from the general population and 379 participants from the 
patient sample. Via the online panel, 3,381 participants from the 
general population received an e-mail about the survey, and 2,136 
responded (response rate 63.2%). Of these, 1,000 met the inclu-
sion criteria of not having a hereditary disease themselves or in 
the family.
Data of non-responders from the population sample showed 
significant differences with those of responders on age (people in 
an older age category more often responded than younger peo-
ple; Χ2(5) = 69.165, p < .001) and education level (more people 
with a lower education level responded compared to people with a 
moderate or high education level; X2(2) = 10.740, p = .005). The num-
ber of non-responders, and thus the response rate and characteris-
tics of non-responders in the patient sample, is unknown. Because 
patient organizations used different media to inform patients and 
relatives about this survey study, it is unknown how many were in-
formed about the survey.
Table 1 shows sociodemographic and clinical characteristics 
of our samples. Respondents from the patient sample were more 
likely to be female (X2(1) = 109.896, p < .001), to have a moderate 
or high education level (X2(2) = 88.026, p < .001), to have children 
(X2(2) = 11.309, p = .001), and to be middle-aged (Χ2(5) = 51.881, 
p < .001).
3.2 | Do people wish to be informed about their 
genetic risks?
Table 2 shows participants' answers on the survey items. The 
population sample was asked whether they wished to be informed 
about genetic risks. Most participants indicated they were in-
terested in knowing whether they were at risk of an autosomal 
dominant disease. This was the case for both treatable conditions 
and untreatable conditions, although the proportions were sig-
nificantly different with a moderate effect size (X2(1) = 54.327, 
p < .001, V = 0.243). The remaining participants indicated in an 
open answer that they would not want to receive this information. 
Others responded that this depends on disease characteristics, 
individual characteristics of relatives (i.e., age, personal circum-
stances), closeness of relatives, and/or whether the proband would 
be able to inform relatives. Chi-square analysis only showed non-
significant or weak significant associations in sociodemographic 
characteristics (see Table 3).
3.3 | Which relatives should be informed?
A majority of participants from the patient and population sample 
indicated that relatives should be informed following the princi-
ples of a cascade screening approach (i.e., only first-degree rela-
tives at first, subsequently second- and further-degree relatives; 
see Table 2). Other options were to inform only first-degree rela-
tives and to inform both first- and further-degree relatives at the 
same time. More participants from the population sample pre-
ferred to inform only first-degree relatives, in contrast to more 
participants of the patient sample preferring to inform first- and 
further-degree relatives at the same time. In the patient sample, 
only a very small minority opted for not informing relatives at all 
(see Table 2). With regard to sociodemographic characteristics, 
participants from the patient sample without children more often 
opted for informing relatives following the principles of cascade 
screening (X2(3) = 13.632, p = .003, V = 0.201). Other characteris-
tics showed nonsignificant or weak significant differences in both 
samples (see Table 3).









N (%) Responders N (%)
Gendera
Female 522 (52.2) 614 (49.3) 300 (79.2)
Male 478 (47.8) 632 (50.7) 79 (20.8)
Agea
18–24 years 83 (8.3) 148 (11.9) 20 (5.3)
25–34 years 157 (15.7) 233 (18.7) 41 (10.8)
35–44 years 134 (13.4) 231 (18.5) 79 (20.8)
45–54 years 171 (17.1) 276 (22.2) 102 (26.9)
55–64 years 188 (18.8) 153 (12.3) 84 (22.2)
≥ 65 years 267 (26.7) 205 (16.5) 53 (14.0)
Education levela,b
Low 311 (31.1) 310 (24.9) 25 (6.5)
Moderate 398 (39.8) 543 (43.6) 186 (49.1)
High 291 (29.1) 393 (31.5) 159 (41.9)
Childrena
Yes 620 (62.6) 719 (57.7) 274 (72.3)
No 370 (37.4) 508 (40.8) 105 (27.7)
Unknown 10 (0.01) 19 (1.5) 0 (0.0)
Religious
Yes 359 (35.9) Unknown 129 (34.0)
No 641 (64.1) Unknown 250 (66.0)
aSignificant difference between responders in general population and 
patient sample. 
bEducation level: low = elementary school, lower level of secondary 
school, lower vocational training; medium = higher level of secondary 
school, intermediate vocational training; high = higher vocational 
training, university. 
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TA B L E  2   Participants' answers on survey-items
Do you prefer to be informed about genetic 








Yes, always 959 (95.9) 800 (80.0) NA NA NA
No, never 21 (2.1) 123 (12.3)
Otherc 20 (2.0) 77 (7.7)
Which relatives should be informed? In both treatable and untreatable 
conditions
In both treatable and untreatable conditions
At first first-degree relatives, after hereditary 
predisposition in a close relative has been 
established further relatives
531 (53.1) 180 (53.6)
Only first-degree relatives of the person with 
the hereditary disease
332 (33.2) 64 (19.0)
First-degree relatives and other relatives at the 
same time
137 (13.7) 84 (25.0)
No relatives – 8 (2.4)







By someone in the family or by a HCP 549 (54.9) 513 (51.3) 124 (46.1) 29 (48.3) 153 (46.5)
By someone in the family, not by a HCP 214 (21.4) 242 (24.2) 33 (12.3) 8 (13.3) 41 (12.5)
By a HCP 231 (23.1) 208 (20.8) 13 (4.8) 0 (0.0) 13 (3.9)
At first by someone in the family, subsequently 
always by a HCP
– – 94 (34.9) 22 (36.7) 116 (35.3)
Otherb 6 (0.6) 37 (3.7) 5 (1.9) 1 (1.7) 6 (1.8)
How should at-risk relatives be informed?
How should information for relatives be 
provided?
In both treatable and untreatable 
conditions
In both treatable and untreatable conditions
At first limited information with possibility to 
gain more information
542 (54.2) 285 (90.2)
All information should be provided at once 457 (45.7) 31 (9.8)
Otherb 1 (0.1) –





Face-to-face 923 (92.3) 820 (82.0) 132 (43.7)
By phone 25 (2.5) 64 (6.4) 3 (1.0)
By letter 22 (2.2) 80 (8.0) 40 (13.2)
By e-mail 12 (1.2) 21 (2.1) 3 (1.0)
A combination of methods – – 103 (34.1)
Other 18 (1.8) 15 (1.5) 21 (7.0)
Should support with informing at-risk relatives 
be offered?
In both treatable and untreatable conditions
Yes NA 257 (86.5)
No 40 (13.5)
When should support with informing at-risk 
relatives be offered?
In both treatable and untreatable conditions
Always NA 128 (50.0)
Only if patients asks for it 86 (33.6)
Only if the genetic counselor believes that 
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3.4 | Who should inform at-risk relatives?
Table 2 describes the responses in case of a treatable or untreat-
able condition (both for the population and for the patient sample). 
A large proportion of participants from the patient and the popula-
tion sample believed that someone in the family and/or HCPs should 
inform at-risk relatives. Many participants from the patient sample 
also believed that at first someone in the family could inform rela-
tives and that subsequently the HCP should always inform relatives 
(as well). A majority (62.5%) of these participants indicating that the 
HCP should be involved in informing at-risk relatives believed that 
the genetic counselor or clinical geneticist would be the most suit-
able person to do this. Some also considered the medical specialist 
(21.5%) or general practitioner (9.7%) a possibility. The remaining 
participants from both samples reported that only the proband or 
someone else in the family should inform at-risk relatives or that 
only the HCP should inform at-risk relatives. Some participants from 
the patient sample mentioned that this depends on the condition 
Do you prefer to be informed about genetic 
risks? General population sample, N (%) Patient sample, N (%)a
Should genetic counselors contact probands 
after some time?
In both treatable and untreatable conditions
Yes, a few weeks after the test result NA 120 (40.7)
Yes, a few months after the test result 48 (16.3)
Yes, 6 months after the test result 14 (4.7)
Yes, a year after the test result 5 (1.7)
Yes, multiple times 39 (13.2)
No 44 (14.9)
Otherb – 25 (8.5)
How should ethical issues be handled?
May contact details of relatives be looked up 








Yes, this should be allowed 511 (51.1) 496 (49.6) 120 (45.6) 25 (43.9) 145 (45.3)
Yes, this should be allowed and this should also 
be done
391 (39.1) 391 (39.1) 106 (40.3) 14 (24.6) 120 (37.5)
No, this should not be allowed 81 (8.1) 94 (9.4) 37 (14.1) 18 (31.5) 55 (17.2)
Otherb 17 (1.7) 19 (1.9) 0 (0.0) 0 (0.0) 0 (0.0)
Should children of relatives deciding not to 
have predictive DNA testing be informed?
In both treatable and untreatable 
conditions
In both treatable and untreatable conditions
Yes, they should be informed 631 (63.1) 195 (58.7)
Dependent on age of children/disease 
characteristics
247 (24.7) 122 (36.8)
No, this should not be allowed 76 (7.6) 15 (4.5)
Otherb 46 (4.6) 0 (0.0)
Should relatives be directly informed by HCPs 








Yes, HCPs should inform relatives directly in 
this case
607 (60.7) 653 (65.3) 122 (46.0) 15 (25.9) 137 (42.4)
No, HCPs should not inform relatives directly 289 (28.9) 283 (28.3) 41 (15.5) 21 (36.2) 62 (19.2)
Otherb 104 (10.4) 64 (6.4) 102 (38.5) 22 (37.9) 124 (38.4)
Note: NA not applicable, survey item or response item is not included in the survey
aNot all numbers add up to the total number of patient sample participants due to missing data. For the patient sample, participants themselves 
indicated which disease was diagnosed in themselves/their family, and these diseases were categorized by clinical geneticists as: (a) treatable: 
prevention or treatment of the disease is possible, or (b) untreatable: prevention or treatment of the disease is not possible. 
bOther: open answer options are explained in the text 
cConsidered significant based on the Bonferroni-adjusted p-level of p < .010 (0.05/5). 
dConsidered significant based on the Bonferroni-adjusted p-level of p < .008 (0.05/6). Open answer categories were not included in the chi-square 
analysis due to the small numbers resulting in the chi-square analyses being not appropriate. 
TA B L E  2   (Continued)
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TA B L E  3   Chi-square tests of differences between sociodemographic and clinical variables per survey item
Do you wish to be 
informed about 
genetic risks?
General population sample Patient sample
Treatable condition Untreatable condition
In both treatable and untreat-
able conditions
Preferred to be 
informed N (%) p
Effect size 
(V)d N (%) p
Effect 
size (V) N (%) p Effect size (V)
Gender
Males 495 (96.7) .008a Weak 423 (86.0) .560 Weak NA   
Females 464 (99.1)   377 (87.5)      
Education level
Low 293 (30.6) .031 Weak 249 (31.1) .142 Weak NA   
Moderate 389 (40.6)   333 (41.6)      
High 277 (28.9)   218 (27.3)      
Parenthoode
Yes 596 (97.4) .257 Weak 504 (87.3) .423 Weak NA   
No 353 (98.6)   289 (85.5)      
Religion
Yes 340 (96.9) .114 Weak 283 (84.2) .107 Weak NA   
No 619 (98.4)   517 (88.1)      
Which relatives should 
be informed? In both treatable and untreatable conditions In both treatable and untreatable conditions
At first first-degree 
relatives, subsequently 
further-degree relatives N (%) p Effect size (V) N (%) p Effect size (V)
Gender
Males 254 (48.7) .001a Weak 36 (49.3) .045 Weak
Females 277 (57.9)   144 (54.8)   
Education level
Low 137 (44.1) <.001a Weak 12 (54.5) .721 Weak
Moderate 200 (50.3)   89 (53.6)   
High 194 (66.7)   79 (53.4)   
Parenthoode
Yes 317 (51.1) .378 Weak 124 (51.0) .003c Moderate
No 206 (55.7)   56 (60.2)   
Religion
Yes 189 (52.6) .121 Weak 62 (54.4) .151 Weak
No 342 (53.4)   118 (53.2)   
Patient type
Affected NA   121 (53.5) .196 Weak
Carrier    32 (50.0)   
Non-carrier    27 (58.7)   
Who should inform at-
risk relatives? Treatable condition Untreatable condition
In both treatable and untreatable 
conditions
By proband and/or HCP N (%) p
Effect 
size (V) N (%) p
Effect 




Males 263 (52.1) <.001a Weak 247 (48.1) <.001b Weak 34 (48.6) .244 Weak
(Continues)
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Who should inform at-
risk relatives? Treatable condition Untreatable condition
In both treatable and untreatable 
conditions
By proband and/or HCP N (%) p
Effect 
size (V) N (%) p
Effect 
size (V) N (%) p
Effect size 
(V)




Low 172 (55.3) .001a Weak 166 (56.3) .001b Weak 10 (45.5) .525 Weak
Moderate 228 (57.3)   216 (56.1)   67 (42.4)   
High 149 (51.2)   131 (46.3)   76 (53.1)   
Parenthoode
Yes 347 (56.3) .545 Weak 314 (53.0) .929 Weak 98 (42.1) .014 Weak
No 200 (54.3)   196 (54.3)   55 (61.1)   
Religion
Yes 187 (52.2) .096 Weak 172 (50.1) .008b Weak 46 (41.4) .165 Weak




Affected NA   NA   94 (43.4) .280 Weak
Carrier       36 (58.1)   
Non-carrier       23 (52.3)   
How should 
ethical issues be 
handled? Treatable condition Untreatable condition
In both treatable and untreatable 
conditions
Contact details 
of relatives may 
be looked up by 
HCPs in registers N (%) p
Effect 




Males 263 (51.1) .547 Weak 237 (46.1) .008b Weak 29 (42.6) .487 Weak
Females 248 (53.0)   259 (55.5)   116 (46.0)   
Education level
Low 178 (58.0) .110 Weak 158 (51.5) .002b Weak 8 (38.1) .881 Weak
Moderate 199 (51.0)   198 (50.5)   76 (48.1)   
High 134 (46.9)   140 (49.6)   61 (43.3)   
Parenthoode
Yes 332 (54.5) .003a Weak 301 (49.5) .002b Weak 102 (44.0) .427 Weak
No 176 (48.2)   190 (52.3)   43 (48.9)   
Religion
Yes 204 (58.1) .013 Weak 184 (52.4) .561 Weak 47 (43.5) .864 Weak
No 307 (48.6)   312 (49.5)   98 (46.2)   
Patient type
Affected NA   NA   95 (44.6) .052 Weak
Carrier       26 (41.3)   
Non-carrier       24 (54.5)   
TA B L E  3   (Continued)
(Continues)
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testing should be 
informed N (%) p Effect size (V) N (%) p Effect size (V)
Gender
Males 335 (67.4) .002a Weak 34 (47.9) .048 Weak
Females 296 (64.8)   161 (61.7)   
Education level
Low 218 (72.7) .006a Weak 15 (68.2) .094 Weak
Moderate 253 (66.4)   99 (60.7)   
High 160 (58.6)   81 (55.1)   
Parenthoode
Yes 386 (65.6) .790 Weak 148 (61.9) .137 Weak
No 241 (67.6)   47 (50.5)   
Religion
Yes 227 (66.4) .953 Weak 63 (55.8) .697 Weak
No 404 (66.0)   132 (60.3)   
Patient type
Affected NA   133 (59.6) .136 Weak
Carrier    35 (54.7)   
Non-carrier    27 (60.0)   
 Treatable condition Untreatable condition





proband does not 
inform them N (%) p
Effect size 
(V) N (%) p
Effect size 




Males 301 (57.7) <.001a Weak 328 (62.8) .023 0.087 25 (36.2) .065 Weak
Females 306 (64.0)   325 (68.0)   112 (44.1)   
Education level
Low 176 (56.6) .021 Weak 211 (678) .386 0.046 7 (31.8) .520 Weak
Moderate 257 (64.6)   265 (66.6)   69 (43.7)   
High 174 (59.8)   177 (60.8)   61 (42.7)   
Parenthoode
Yes 365 (58.9) .174 Weak 404 (65.2) .967 0.008 102 (43.6) .298 Weak
No 236 (63.8)   243 (65.7)   35 (39.3)   
Religion
Yes 198 (55.2) .011 Weak 219 (61.0) .073 0.072 40 (36.4) .089 Weak
No 409 (63.8)   434 (67.7)   97 (45.5)   
Patient type
Affected NA   NA   77 (35.8) .005c Weak
Carrier       37 (58.7)   
TA B L E  3   (Continued)
(Continues)
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involved. As shown in Table 3, a significant difference with moder-
ate effect size was observed between attitudes in case of a treatable 
or untreatable disease in the population sample, although again no 
clear direction of the difference could be identified (X2(4) = 624.261, 
p < .001, V = 0.243). Only nonsignificant or weak associations in so-
ciodemographic factors were shown.
3.5 | How should information for at-risk relatives be 
provided?
3.5.1 | Stepwise information provision
Almost all participants from the patient sample believed that the 
first information provided to relatives should be concise, with the 
possibility to receive more information (see Table 2). Only a small 
minority held the opinion that all available information should be 
handed over at once. In contrast, almost half of participants from 
the population sample believed that all information should be pro-
vided at the same time. The other half believed that at first limited 
information should be provided with the possibility to gain more 
information. One participant from the population sample reported 
to be unsure.
3.5.2 | Medium used to inform relatives
As shown in Table 2, many participants from the population and 
the patient sample preferred to inform relatives in a personal 
manner (i.e., face-to-face). Other participants from both samples 
preferred information provided by telephone, letter, or e-mail. 
The remainder filled out the open answer option, all answering 
that the type of medium used would depend on the closeness of 
relatives.
3.5.3 | Support by HCPs
The patient sample was additionally asked for their opinion regard-
ing support offered by HCPs in general. A majority of participants 
believed support should be offered by HCPs, with half believing this 
should always be offered. Others believed that this should only be 
done if patients ask for it, that this should only be offered when the 
HCP thinks that support is needed, or that this depends on the situa-
tion (see Table 2). In addition, a majority of patients and relatives pre-
ferred follow-up contact by their genetic counselor. A large proportion 
believed that genetic counselors should ideally do this a few weeks 
after receiving the test result. Others believed that this should be 
done a couple of months after receiving the test result or that patients 
should be contacted multiple times after receiving the test result.
3.6 | How should ethical issues be handled?
3.6.1 | Contact details of relatives in 
population registers
In clinical genetic practice, one sometimes encounters that probands 
do not have any contact details of at-risk relatives and therefore can-
not inform relatives. In this situation, a large proportion of partici-
pants from both samples believed clinical genetic practices should 
be allowed to look up contact details of relatives in population regis-
ters (see Table 2). An additional 39.1% of the population participants 
(in case of both treatable and untreatable disease) and 37.5% of pa-
tients and relatives thought this should even be obligatory.
Preferences in the population sample differed significantly for treat-
able versus untreatable conditions showing a strong effect size, although 
no clear direction of the difference was observed (X2(4) = 826.710, 
p < .001, V = 0.652; see Table 3). In both samples, only nonsignificant or 
weak significant associations were shown in other factors.
 Treatable condition Untreatable condition





proband does not 
inform them N (%) p
Effect size 
(V) N (%) p
Effect size 
(V) N (%) p
Effect size 
(V)
Non-carrier       23 (51.1)   
Note: NA, not applicable, survey item not included in the survey, or comparison of treatable and untreatable conditions; N (%): percentage within category
aConsidered significant based on the Bonferroni-adjusted p-level of p < .010 (0.05/5) 
bconsidered significant based on the Bonferroni-adjusted p-level of p < .013 (0.05/4) 
cconsidered significant based on the Bonferroni-adjusted p-level of p < .008 (0.05/6). Open answer categories were not included in the chi-square 
analysis due to the small numbers resulting in the chi-square analyses being not appropriate. 
dEffect size using Cramer's V: weak effect size = Cramer's V < 0.20; moderate effect size = Cramer's V = 0.20–0.30; strong effect size = Cramer's V > 0.30 
eDue to missing values regarding parenthood (unknown: N = 10) in the general population sample, the total numbers differ from Table 2. 
TA B L E  3   (Continued)
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3.6.2 | Informing children of relatives who 
decide not to have predictive DNA testing
In both the patient sample and the population sample, more than 
half of participants believed that the children of relatives who decide 
not to get tested should be informed (see Table 2). Some participants 
believed this depends on the age of children, whether preventive or 
treatment options are available, and whether there are reproductive 
possibilities. A few participants gave an open answer that this is the 
responsibility of parents. Some did not elaborate on their opinion 
but considered this an ethical dilemma (see Table 2). As shown in 
Table 3, chi-square analysis showed only nonsignificant or weak sig-
nificant associations in sociodemographic and clinical characteristics 
in both samples.
3.6.3 | Directly informing relatives by HCPs 
when the proband prefers not to inform relatives
Participants were also asked whether at-risk relatives should be 
informed if the proband is unwilling to. A large proportion of the 
patient sample believed that HCPs should inform relatives in this 
case. A larger percentage of participants of the population sample 
shared this opinion. This was the case in treatable and untreatable 
conditions, although a significant difference with a strong effect 
size was found (X2(4) = 572.868, p < .001, V = 0.535). Also, a large 
proportion of the patient sample filled out the open answer option, 
indicating that they believed this depended on whether there were 
preventive or treatment options or reproductive options, and/or, in 
case of minors, the age of relatives (see Table 2). Participants with 
an untreatable hereditary disease themselves or in their family more 
often believed relatives should not be informed when the proband is 
unwilling to inform, showing a moderate association (X2(2) = 15.229, 
p < .001, V = 0.217). Only nonsignificant or weak associations were 
found in the patient sample.
4  | DISCUSSION
In the present study, we have assessed the preferences of Dutch 
probands and relatives, and members of the general population on 
how to inform at-risk relatives of autosomal dominant diseases. Our 
findings show that many participants preferred that the proband in-
forms at-risk relatives. However, a majority believed HCPs should 
also be involved in this information process. There was an agreement 
between the patient and population sample on this matter. Previous 
research also indicated that patients and relatives often prefer the 
proband to inform relatives, because this seems the most logical ap-
proach (Forrest et al., 2003; Keenan et al., 2005; Leenen et al., 2016; 
Pentz et al., 2005).
Active involvement of HCPs was, however, desired by both our 
patient and population sample. Our findings indicate that HCPs 
should primarily engage in a supportive role, supporting probands 
in informing at-risk relatives by providing information and provid-
ing help if probands are unable or unwilling to inform relatives. 
Some participants were in favor of direct contact by HCPs in all 
cases. Interestingly, a majority of participants from the general 
population preferred relatives to be informed personally, in case 
of both a family-mediated and a direct contact approach. This 
suggests that personal contact between relatives and HCPs might 
be considered beneficial, including when using a direct contact 
approach.
Most participants preferred the principles of a cascade 
screening approach. This is also the most logical approach from 
a healthcare perspective, since relatives with the highest risk are 
approached at first (Miller et al., 2013). In addition, psychological 
harm for second-degree relatives with a connecting first-degree 
relative who does not have the genetic predisposition can be pre-
vented (Miller et al., 2013; Van Langen, Hofman, Tan, & Wilde, 
2004). However, previous studies suggest that the process of cas-
cade screening often breaks down and further-degree relatives are 
not reached (Burns et al., 2016; Shah et al., 2018). Interestingly, a 
majority of participants in our study believed that in case a rela-
tive decides to not get tested, connecting second-degree relatives 
should be informed.
Our findings show that information material for relatives pro-
vided by HCPs was generally desired. Previous studies suggested 
that educational material should be provided in a stepwise manner, 
with only limited information at first (Ratnayake et al., 2011; Van den 
Nieuwenhoff, Mesters, Nellissen, Stalenhoef, & de Vries, 2006). In 
the present study, a majority of participants from the patient sample 
also preferred to receive information in a stepwise manner. Almost 
all members of the general population participating in this study, 
however, believed all available information for relatives should be 
provided at once. This difference might be explained by the fact that 
patients and relatives have experienced the process of informing at-
risk relatives, while it remains a hypothetical situation for members 
of the general population.
We additionally explored what participants believed about 
handling situations where ethical issues are at stake. In current 
practice, clinical genetic practice relies on the proband to inform 
at-risk relatives, thereby retaining patient confidentiality and rela-
tives' right not to know. These ethical principles are, however, also 
at stake when patients share with their genetic HCP that they do 
not intend to inform at-risk relatives. Importantly, a majority of 
participants believed that HCPs should directly contact relatives 
in cases where the proband is unwilling to inform at-risk relatives. 
Furthermore, a majority believed that clinical genetic centers 
should be allowed to use population registers to retrieve contact 
details of at-risk relatives, if unavailable via the proband. The pos-
sibility to become aware of genetic risks therefore seems to be 
an important issue for a majority of probands, relatives, and the 
general population (Petersen et al., 2019; Sermijn et al., 2016). In 
treatable conditions, the ‘right to know’ might be considered more 
important than patient confidentiality, as indicated in a previous 
qualitative study in the Netherlands (Van den Heuvel et al., 2019). 
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This was also felt by HCPs, as they feel a responsibility not to harm 
relatives by leaving them unaware of their genetic risk (Van den 
Heuvel et al., 2019).
Attitudes toward informing relatives in case of treatable versus 
untreatable hereditary conditions were assessed as well. Although 
the majority of both samples was in favor of informing relatives 
in both treatable and untreatable hereditary conditions, some 
differences were observed. As can be hypothesized, the avail-
ability of prevention and treatment options seemed to influence 
preferences regarding how relatives should be informed, with par-
ticipants being more inclined to believe that relatives should be 
informed in cases of treatable hereditary conditions. In the pa-
tient sample, this was primarily observed in preferences regarding 
ethical issues. In the population sample, significant differences 
were observed on quite a few survey items, although no clear 
direction of the difference could be observed and associations 
were often weak. This can be explained by the large sample size, 
which may lead to small differences being statistically significant. 
Furthermore, the population sample was asked to consider a hy-
pothetical situation of being at risk for a treatable and untreatable 
condition, while the patient sample was asked to fill out the survey 
based on their own disease.
4.1 | Implications for clinical practice
As illustrated by Burns et al. (2018), informing relatives is a complex 
process that requires the proband to be able to correctly convey the 
information and relatives to understand the information and connect 
this to appropriate services. Current clinical genetic practice may be 
insufficient considering the low uptake of genetic counseling. Our 
findings suggest that there is a need for other approaches with a 
more active role of HCPs to provide sufficient support for probands 
in informing at-risk relatives of autosomal dominant diseases. The 
field of genetic counseling may therefore consider ways to actively 
support the proband in informing relatives, for example, by provid-
ing a family letter and educational material. This educational mate-
rial should contain information not only on the familial disease, but 
also on what probands can encounter when informing relatives. 
Furthermore, follow-up contacts by HCPs with probands and rela-
tives with the genetic predisposition regarding informing at-risk 
relatives should be incorporated in this approach to facilitate the 
information process. As stated by Schwiter et al. (2018), cascade 
testing should not be a one-time conversation. One could, however, 
imagine that a more active role of HCPs in informing at-risk relatives 
may also have downsides, such as higher workload or less time to 
see other patients. Furthermore, time spent on relatives who are not 
registered as patients yet cannot be billed.
The findings of this study contribute to our understanding of 
patient attitudes toward the approach used to inform at-risk rela-
tives. Moreover, to our knowledge, little was known on preferences 
of the general population prior to this study. The current findings are 
particularly important as the general population includes individuals 
who may be informed about a genetic disease risk in the future. Our 
findings suggest that the views of the general population generally 
corresponded with the views of patients and relatives. Regarding 
uptake of genetic counseling, a direct contact approach seems to 
be the most optimal (Aktan-Collan et al., 2007; Sermijn et al., 2016; 
Suthers et al., 2006). Our findings, however, indicate that partici-
pants prefer both patients and HCPs to be involved in informing at-
risk relatives and not solely HCPs. To be effective in clinical genetic 
practice, it is essential that the approach used to inform at-risk rela-
tives is acceptable and feasible for all stakeholders. Further research 
is therefore needed to compare other more active approaches incor-
porating these preferences, ideally using intervention studies.
4.2 | Limitations
This study had several limitations. Since only Dutch participants 
were included in the survey, these results cannot be generalized 
to other populations. Besides, the patient sample and population 
sample survey were slightly different and significant differences 
between both samples in sociodemographic characteristics were 
observed. The patient sample included in this survey study was also 
smaller than the population sample. For these reasons, comparison 
of both surveys was not optimal. Furthermore, the surveys for the 
patient sample and population sample were not piloted, thereby po-
tentially administering unclear questions.
Unfortunately, it was not possible to determine a response rate 
in patients and relatives. In addition, a response bias in patients and 
relatives could be present. Patients who experienced problems in 
informing at-risk relatives were possibly more inclined to partici-
pate. However, having negative experiences with informing at-risk 
relatives may also have caused patients to not participate in the sur-
vey. Relatives who had a positive attitude to being informed about 
the hereditary disease in their family were probably also more in-
clined to participate than relatives who did not. The comparison of 
responders and non-responders of the general population sample 
showed significant differences in age and education level, indicating 
a response bias in this sample as well. The high rate of participants 
in the population survey indicating to have a genetic disease also in-
dicates that there was a bias in people signing up for the FlyCatcher 
research surveys. However, a genetic disease in the family can be in-
terpreted in a broad sense, including Down syndrome in a fourth-de-
gree relative. This general exclusion criterion resulted in participants 
that are unaware of a genetic disease in their family, which is what 
we aimed for.
5  | CONCLUSIONS
This survey study on preferences regarding informing at-risk rela-
tives of autosomal dominant diseases showed that a majority of 
Dutch patients and relatives, as well as Dutch members of the gen-
eral population, generally felt that both the proband and the HCP 
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should be involved in informing relatives at risk of autosomal domi-
nant diseases. Support of HCPs was, however, desired, including the 
provision of educational material for relatives and follow-up contacts 
with the proband. Breaching patient confidentiality was considered 
an ethical issue, although most participants believed informing at-risk 
relatives was more important. Incorporating these preferences into 
the approach used to inform at-risk relatives may increase the num-
ber of (adequately) informed relatives, and therefore enable more 
at-risk relatives to make an informed decision regarding predictive 
DNA testing. Further research, specifically intervention studies, on 
novel approaches incorporating these preferences to inform at-risk 
relatives of autosomal dominant diseases is needed.
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